Search
Search Results
##search.searchResults.foundPlural##
-
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3349PDF: 1711HTML: 410 -
The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study
2714PDF: 1040HTML: 398 -
MIR-140 TARGETS LNCRNA DNAJC3-AS1 TO SUPPRESS CELL PROLIFERATION IN ACUTE MYELOID LEUKEMIA AML proliferation and MIR-140 LNCRNA DNAJC3-AS1 target.
1362PDF: 689HTML: 332 -
EARLY PREDICTIVE VALUE OF PERIPHERAL INFLAMMATORY INDEX COMBINED WITH HIGH-SENSITIVITY TROPONIN T FOR SEPSIS-INDUCED CARDIOMYOPATHY Inflammatory and Troponin T in cardiomyopathy from Sepsis
448PDF: 438HTML: 237 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
1113PDF: 599HTML: 350 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
2048PDF: 1267HTML: 356 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3652PDF: 1496HTML: 2748 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1950PDF: 666HTML: 379 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1923PDF: 2144Suppl. Files: 297HTML: 126 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
3031PDF: 1045HTML: 664 -
WHAT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA TAUGHT US ABOUT TRANSPLANT IMMUNOGENETICS.
3346PDF: 1215HTML: 1707Untitled: 230Untitled: 230Untitled: 215 -
ANTIBACTERIAL RESISTANCE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
4257PDF: 1349HTML: 2130Table 1: 243 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1598PDF: 1430HTML: 125 -
TREATMENT OF EARLY STAGES HODGKIN LYMPHOMA DURING PREGNANCY
4306PDF: 1193HTML: 925 -
POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia
682PDF: 313HTML: 181 -
FIRST-PHASE INSULIN RESPONSE (FPIR) TO INTRAVENOUS GLUCOSE TOLERANCE TEST (IVGTT), INSULIN SENSITIVITY AND LONG-TERM FOLLOW-UP IN TRANSFUSION-DEPENDENT BETA-THALASSEMIA (TDT) NORMOGLYCEMIC PATIENTS WITH REDUCED INSULIN SECRETION TO ORAL GLUCOSE TOLERANCE TEST: A PILOT STUDY. The function of the endocrine pancreas in transfusion-dependent ?-thalassemia
7676PDF: 673HTML: 378 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
5227PDF: 3025HTML: 2384 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3375PDF: 1449HTML: 4170 -
CHILDREN IN CORONAVIRUSES’ WONDERLAND: WHAT CLINICIANS NEED TO KNOW Corona virus and Children
1626PDF: 1053HTML: 536 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1293PDF: 829HTML: 1552Figure 1: 277Figure 2: 298 -
APPROPRIATE DURATION OF INTRAVENOUS TREATMENT OF CANDIDEMIA AND TIMING OF STEP DOWN TO ORAL THERAPY IN NON-NEUTROPENIC PATIENTS
3026PDF: 1191HTML: 522Preferred Reviewers: 256 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
2261PDF: 858HTML: 3288 -
A Case of Rupioid Syphilis Masquerading as Aggressive Cutaneous Lymphoma
2853PDF: 1141HTML: 5147Cover Letter: 212Figure 2: 217Figure 1: 224Figure 3: 250Figure 4: 244Figure Legend: 237Table 1: 248Table 2: 230Table 3: 225 -
Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia
3043PDF: 763HTML: 1975figure 1: 234figure 2: 225 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1850PDF: 875HTML: 935jdoe, table 2 infections CML .doc: 256jdoe, table 1 infections CML .doc: 233







